Literature DB >> 19259029

Olanzapine: a new risk factor for pulmonary embolus?

Rajesh Kannan1, D Kimberley Molina.   

Abstract

Pulmonary embolus (PE) is not an uncommon cause of sudden death, and forensic pathologists are not unaccustomed to being the first to diagnose a PE in a patient, since they are often fatal. Forensic pathologists are also familiar with the known risk factors for development of PEs, including advanced age, use of oral contraceptives, smoking, obesity, a sedimentary lifestyle, postsurgery or postinjury, pregnancy, certain malignancies, factor V Leiden and prothrombin mutations, and anticardiolipin antibodies. It has recently been shown in the clinical literature that antipsychotic medications are associated with an increased risk of thromboembolic events. Clozapine, a close relative of olanzapine, has been implicated as an independent risk factor for developing a PE. Four cases have been published within the last 2 years questioning whether olanzapine may also be associated with an increased risk for PE. We report 6 cases from the Bexar County Medical Examiner's Office, occurring between 1998 and 2005 where olanzapine may have been a risk factor in the development of, and death from, PE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19259029     DOI: 10.1097/PAF.0b013e31818736e0

Source DB:  PubMed          Journal:  Am J Forensic Med Pathol        ISSN: 0195-7910            Impact factor:   0.921


  3 in total

1.  Olanzapine and pulmonary embolism, a rare association: a case report.

Authors:  Julian Fz Maempel; Geraldine Darmanin; Kashif Naeem; Mehool Patel
Journal:  Cases J       Date:  2010-01-22

2.  Arrhythmogenic right ventricular cardiomyopathy in a patient with schizophrenia.

Authors:  Kenta Kawasaki; Kotaro Miyaji; Satoshi Kodera; Yoshio Suzuki; Junji Kanda; Masayuki Ikeda
Journal:  Clin Case Rep       Date:  2015-02-19

3.  Rare and Underestimated Association of Pulmonary Embolism and Olanzapine Therapy; Report of Two Cases.

Authors:  Hammam Rasras; Mustapha Beghi; Maryem Samti; Nabila Ismaili; Noha El Ouafi
Journal:  Arch Acad Emerg Med       Date:  2021-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.